Tarsus to Report Third Quarter 2024 Financial Results on Wednesday, November 13, 2024

Rhea-AI Impact

(Low)

Rhea-AI Sentiment

(Neutral)

Rhea-AI Summary

Tarsus Pharmaceuticals (NASDAQ: TARS) has scheduled its third quarter 2024 financial results announcement and corporate update for Wednesday, November 13, 2024, at 1:30 p.m. PT / 4:30 p.m. ET. The company will host a live webcast of the event, which will be archived on their website for approximately 90 days following the presentation.

11/06/2024 - 04:30 PM

IRVINE, Calif., Nov. 06, 2024 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), whose mission is to focus on unmet needs and apply proven science and new technology to revolutionize treatment for patients, starting with eye care, today announced that it will host a live webcast at 1:30 p.m. PT / 4:30 p.m. ET on Wednesday, November 13, 2024 to report its third quarter 2024 financial results and provide a corporate update.

Participants may access the webcast here. A recorded version of the call will be available on the website shortly after the completion of the webcast and will be archived there for approximately 90 days.

About Tarsus Pharmaceuticals, Inc.
Tarsus Pharmaceuticals, Inc. applies proven science and new technology to revolutionize treatment for patients, starting with eye care. Tarsus is advancing its pipeline to address several diseases with high unmet need across a range of therapeutic categories, including eye care, dermatology and infectious disease prevention. XDEMVY^® (lotilaner ophthalmic solution) 0.25% is FDA approved in the United States for the treatment of Demodex blepharitis. Tarsus is also developing TP-03 as an investigational therapy for the treatment of Meibomian Gland Disease, TP-04 for the treatment of rosacea and TP-05 as an oral tablet for the prevention of Lyme disease, all of which are in Phase 2.

Media Contact:
Adrienne Kemp
Sr. Director, Corporate Communications
(949) 922-0801
AKemp@tarsusrx.com

Investor Contact:
David Nakasone
Head of Investor Relations
(949) 620-3223
DNakasone@tarsusrx.com

FAQ

When will Tarsus Pharmaceuticals (TARS) report Q3 2024 earnings?

Tarsus Pharmaceuticals will report its Q3 2024 financial results on Wednesday, November 13, 2024, at 1:30 p.m. PT / 4:30 p.m. ET.

How can I access Tarsus Pharmaceuticals (TARS) Q3 2024 earnings webcast?

The earnings webcast can be accessed through the company's website, and a recorded version will be available for approximately 90 days after the event.